Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Date:11/17/2009

cancers is currently underway in the U.S. Interim results from both the U.K. and the U.S. studies formed the basis for the Company's decision to conduct a Phase III pivotal program looking at REOLYSIN in combination with carboplatin/paclitaxel in this patient population. The Company has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of the Phase III trial.

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
2. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
6. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
7. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
9. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
11. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... will provide new insights on mechanics of fecal microbiota transplantation in C. difficile ... study the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment ...
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., a leading ... a paper published this week in the scientific journal Viruses ( http://www.mdpi.com/1999-4915/7/6/2763 ), ... currently used to detect the Ebola virus. Noblis worked with the Department of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC , a ... Gem Swartz to head up its account management department as vice president of client ... Amanda bring senior account management and delivery expertise to the growing Matrix Marketing Group ...
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, Inc. ... that they are silver sponsors of the Primary Care ... sponsor, Custom is lending their support of PCDC,s mission ... Since its founding in 1993, PCDC has ... care area.  PCDC has financed over 100 completed primary ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Matrix Marketing Group Expands Client Services Team 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2
... 28, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... extension study (MOR-100) in which patients have continued treatment on ... the initial Phase 1/2 study of GALNS (MOR-002) were continued ... MOR-100 study, patients were treated at a 2.0 mg/kg/week dose ...
... AllograftPossibilities.org has rapidly grown into the premier ... on the web. Although it has the same life-saving ... still lesser understood by the general public. The nonprofit ... of bone and soft-tissue allografts for use in surgical ...
... SAN DIEGO, July 28, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... of its 5.5% Notes and approximately $3 million in ... are very pleased to have taken another important step ...
Cached Biology Technology:BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 2BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 3BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 4BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 5BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 6AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 2AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 3Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... (CHICAGO - Sept. 30, 2009) U.S. Environmental Protection Agency,s ... of a dioxin exposure study conducted by the University ... the study was conducted well and provided useful, scientifically ... to help EPA fully evaluate human exposure to levels ...
... KINSTON, N.C., Oct. 1 Spatial Integrated Systems, ... integration of solutions incorporating next-generation digital 3D data ... United States patent application has been published for ... 3-dimensional image rendering" under Publication No. US2009/0169095A1. , ...
... University of Warwick and Rothamsted Research have been awarded ... (BBSRC) in partnership with Syngenta, to research the decline ... have fallen by 10-15% over the last 2 years; ... 30% for 2008. Since the declines were first reported ...
Cached Biology News:EPA reviews Univ. of Michigan dioxin study 2Spatial Integrated Systems, Inc. Files Patent Application 2£1 million award to address honeybee decline 2£1 million award to address honeybee decline 3